CLRPF (Clarity Pharmaceuticals) Pre-Tax Income : $-28.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Clarity Pharmaceuticals's pretax income for the six months ended in Dec. 2023 was $-11.44 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-28.00 Mil. Clarity Pharmaceuticals's pretax margin was %.

Clarity Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Clarity Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Pre-Tax Income Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Jun24

Pre-Tax Income

-16.68

-16.44

-27.91

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial			-7.05	-7.55	-8.94	-11.44	-16.55

Competitive Comparison of Clarity Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Clarity Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's Pre-Tax Income falls into.

Clarity Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Clarity Pharmaceuticals's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-24.271	+	6.578	+	0	+	1.251	+	0
	=	-16.44

Clarity Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-15.807	+	3.627	+	0	+	0.736	+	-1.7763568394003E-15
	=	-11.44

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-28.00 Mil.

Clarity Pharmaceuticals (OTCPK:CLRPF) Pre-Tax Income Explanation

Clarity Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-11.444	/	0
	=	%

Clarity Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

CU6:Australia

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States.